NICE National Institute for Health and Care Excellence

NICE guidance

Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)

Technology appraisal guidance
Published: 24 April 2013
www.nice.org.uk/guidance/ta281

Contents

Advice

NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks because no evidence submission was received from the manufacturer of the technology.

Background

The manufacturer of canakinumab (Novartis) was invited to submit evidence for the single technology appraisal of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks.

The manufacturer informed NICE that it would not be making an evidence submission for this appraisal. The manufacturer stated that it will not be promoting canakinumab for this specific indication in the UK.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks. If, after doing this, organisations still wish to consider canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks, they should follow the advice set out in the Department of Health's 'Good practice guidance on managing the introduction of new healthcare interventions and links to NICE technology appraisal guidance', which outlines the approach that should be adopted in circumstances where NICE guidance is unavailable.

NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.

Related NICE guidance

For information about NICE guidance that has been issued or is in development, see the NICE website.

Published

- Febuxostat for the management of hyperuricaemia in people with gout. NICE technology appraisal guidance 164 (2008).

Under development

NICE is developing the following guidance:

- Pegloticase for treating severe debilitating chronic tophaceous gout. NICE technology appraisal. Publication expected June 2013.

Accreditation